Real-World Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Relapsed or Refractory Multiple Myeloma: Evidence from a Medical Record Review in France

<table class="figure-group"><tr class="fig-image" id="a"><td><object data="https://static.hindawi.com/articles/ah/volume-2019/4625787/figures/4625787.fig.001a.svgz" name="4625787.fig.001a" type="image/svg+xml"></object></td></tr><tr class="fig-caption"><td><b>(a) </b>Second-line treatment (n = 192)</td></tr><tr class="fig-image" id="b"><td><object data="https://static.hindawi.com/articles/ah/volume-2019/4625787/figures/4625787.fig.001b.svgz" name="4625787.fig.001b" type="image/svg+xml"></object></td></tr><tr class="fig-caption"><td><b>(b) </b>Third-line treatment (n = 114)</td></tr></table>

<div>Second- and third-line treatment regimens. Note: regimen compositions listed are irrespective of concomitant dexamethasone use.</div>

Advances in Hematology

fig1

Figure 1

Figure 1: Real-World Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Relapsed or Refractory Multiple Myeloma: Evidence from a Medical Record Review in France 

Figure 1 | Real-World Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Relapsed or Refractory Multiple Myeloma: Evidence from a Medical Record Review in France 